The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Celldex Therapeutics Inc (NASDAQ: CLDX) closed the day trading at $19.88 down -0.35% from the previous closing price of $19.95. In other words, the price has decreased by -$0.35 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
For a better understanding of CLDX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.91 and its Current Ratio is at 18.91. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on March 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $46.
On February 13, 2025, UBS started tracking the stock assigning a Buy rating and target price of $44.
On October 07, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $70.Citigroup initiated its Buy rating on October 07, 2024, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 187.99 while its Price-to-Book (P/B) ratio in mrq is 1.77.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $47.00, while it has fallen to a 52-week low of $18.61. The 50-Day Moving Average of the stock is -11.50%, while the 200-Day Moving Average is calculated to be -34.29%.
Shares Statistics:
A total of 66.37M shares are outstanding, with a floating share count of 64.70M. Insiders hold about 2.54% of the company’s shares, while institutions hold 109.76% stake in the company.
